INNOVATING TOGETHER

Making precision medicine possible in infectious disease.

Combating antibiotic resistance

The Shield team is united in our vision to provide clinicians with the ability to adopt a precision medicine approach to the most pressing infections, so that patients are provided with the highest standard of care and first line antibiotics can continue to be an invaluable tool. We are a CLIA lab located in San Jose, CA.

Leadership

Fred Turner

CEO and Co-Founder

Fred Turner

Fred Turner is a board member and the CEO and Co-Founder of Shield. He was featured along with Sam Parlett in Forbes 30 Under 30 in 2018 for co-founding TL Biolabs, a precursor to Shield focused on advanced genetic and genomic testing solutions for the agricultural industry. In 2013 he was awarded the UK Young Engineer title by The National Science + Engineering Competition and won the European Young Scientist title in the European Union Contest, as well as being named one of the top 100 practicing scientists in the UK by the UK Science Council. Fred studied at Oxford University and is also a Thiel Fellow.

Sam Parlett

President and Co-Founder

Sam Parlett

Sam Parlett is the President and Co-Founder of Shield. Along with Fred Turner, he was featured in Forbes 30 Under 30 in 2018 for co-founding TL Biolabs, a precursor to Shield focused on advanced genomic testing solutions for the agricultural industry. Prior to that he built the UK arm of Theodo, a software services company, where, as the Business Development and Project Director, he helped the company triple in size. His previous entrepreneurial ventures, Synergy Startups and Forge, were both based in London UK. Sam holds a M.Sc from the University of Oxford and a B.Sc from the University of Sussex.

Vlad Slepnev

Vice President
Research & Development

Vlad Slepnev

Vlad Slepnev, PhD, leads R&D at Shield, building uniquely impactful & convenient diagnostic tests. He is an experienced leader in molecular diagnostic research & development with a demonstrated history of bringing IVD tests to market. He was Co-Founder and CTO at Primera Dx, where he built a new molecular diagnostic platform and participated in raising >$50M before being acquired by Qiagen. Subsequently, as a Senior Director at Meridian he developed 9 510(k) cleared and 11 CE marked molecular diagnostic tests in 7 years. Vlad did his PhD studies at Moscow State University and Post-docs at the Pasteur institute (France) and Yale University. He has works published in Cell, Science & Nature.

Jill MacAfee

Director
Clinical Laboratory Operations

Jill MacAfee

Jill MacAfee, CLS(ASCP), MBA, is the Director of Clinical Laboratory Operations, ensuring the highest levels of test quality at Shield. She has been a general and technical supervisor for 30 years at labs such as Singulex and Genos, and Director of Laboratory Services at Planned Parenthood’s highest volume STI laboratories. She has been a speaker on technical aspects of laboratory medicine and public health, a mentor and teacher in laboratory QA, technology and procedures, and a troubleshooting expert for automated analyzers. She built 8 CLIA/CAP accredited labs, including hospital, commercial and not-for-profit labs, from the ground up, and served as a New York Quality Systems Manager for 1.5 years, yielding a highly successful NY site inspection. Jill designed and implemented the clinical trials program at PPMM; served as Technical Advisor for Planned Parenthood Federation of America, monitored and documented quality systems, and trained staff at over 50 clinic-based laboratories, building a strong reputation for excellence in patient care.

Arthur Baca

Laboratory Director

Arthur Baca

Dr. Arthur Baca is our CLIA Laboratory Director. He received his medical training at the University of Washington and pathology training at the University of California, San Francisco. He has served as a Laboratory and Medical Director at various genomic-based companies, including Berkeley HeartLab, AltheaDx, Human Longevity, Quest Diagnostics and Guardant Health. Dr Baca is a physician-scientist with experience in laboratory medicine practiced in a high-volume commercial setting. His particular focus is on delivering quality laboratory results for personalized medicine, with expertise in esoteric high-complexity chemistry and molecular genetic testing.

Shahar Or-Geva

Director
Finance and Administration

Shahar Or-Geva

Shahar Or-Geva, MBA, leads finance & administration at Shield, ensuring we have a tightly run ship. He started his career in the military and was a company commander of 120 soldiers in the Israeli Defense Force. Subsequently, he was an economic advisor to the Director General at the Israeli Ministry of Agriculture and then the COO of the Israeli Cattle Breeders Association where he turned them around from operational loss to profitability whilst simultaneously earning an executive MBA from the Kellogg School of Management. Thereafter he was a strategic consultant in industries ranging from software to clean tech.

Melissa Kamita

Director
Human Resources

Melissa Kamita

Melissa Kamita leads Human Resources at Shield, building a world class team with a close knit culture. She draws upon more than two decades of HR experience in industries ranging from non-profits to medical device manufacturing, spanning both start-ups and global companies. As the head of HR at Ariosa Diagnostics she built a hyper-growth team, growing 7x in under 3 years, and she stayed on as Director of HR at Roche Sequencing Solutions subsequent to their acquisition. Previously she was a Sr. HR Business Partner at Dionex, which was acquired by Thermo Fisher. Melissa has a BA focused in Communications from UC Santa Barbara.

Michael Newton

Director
Sales

Michael Newton

Michael Newton leads sales at Shield, ensuring we provide a seamless patient & clinic experience. An accomplished commercial leader, he has a track record of high sales performance and people development internationally in pharmaceuticals & diagnostics. Michael built a sales force of 60 from scratch at Ariosa in an eighteen month period, driving impressive revenues until Ariosa’s acquisition by Roche. Subsequently, he was a National Director of Market Intelligence at Roche, successfully launching the Avenio ctDNA Oncology Assay. Previously, he was a Regional Sales Director at Valeant Dermatology, where his 65-person team was frequently placed best in the nation.

Margaret Theeuwes

Vice President
Marketing

Margaret Theeuwes

Margaret is the VP of Marketing at Shield. She has held a variety of US & international marketing roles in the molecular diagnostics, pharmaceutical and consumer sectors. She was the head of Global Marketing at Roche Sequencing Solutions, VP of Marketing at Ariosa Diagnostics, and whilst at Johnson and Johnson she led the marketing efforts for the dermatology audience at Neutrogena & retail and hospital sectors for Levaquin (an anti infective). She excels at cross-functional team collaboration, lifecycle management, new product launches, and in-line product and brand management to maximize brand equity and commercial performance in the regulated healthcare market. Margaret has an MD from the University of Leuven, Belgium.

Board

Fred Turner

CEO and Co-Founder

Fred Turner

Fred Turner is a board member and the CEO and Co-Founder of Shield. He was featured along with Sam Parlett in Forbes 30 Under 30 in 2018 for co-founding TL Biolabs, a precursor to Shield focused on advanced genetic and genomic testing solutions for the agricultural industry. In 2013 he was awarded the UK Young Engineer title by The National Science + Engineering Competition and won the European Young Scientist title in the European Union Contest, as well as being named one of the top 100 practicing scientists in the UK by the UK Science Council. Fred studied at Oxford University and is also a Thiel Fellow.

David Esposito

CEO ONL Therapeutics

David Esposito

David a board member at Shield and the CEO of ONL Therapeutics based in Ann Arbor. He is the former CEO of Armune BioScience where he led the development and commercialization of blood-based diagnostics to enable more personalized treatment for cancer. Armune BioScience was sold to Exact Sciences in 2017. Previously, Esposito was President of Phadia US Inc. (allergy and autoimmune diagnostics) and played a pivotal role in selling the business to Thermo Fisher Scientific in 2011. Mr. Esposito is a combat veteran, led an infantry platoon with the 101st Airborne Division through several combat operations, and was recognized with a Bronze Star for combat action in Iraq in 1991. David earned his B.S. degree in Civil Engineering from the United States Military Academy at West Point and his MBA from Syracuse University.

Zal Bilimoria

Managing Partner, Refactor Capital

Zal Bilimoria

Zal is a board member at Shield and Managing Partner at Refactor Capital. Prior to co-founding Refactor, Zal spent 2+ years at Andreessen Horowitz as a Partner on the investing team working across stages & sectors. He co-led investments in Omada Health, Branch.co, AltSchool, Honor, uBiome, etc., while helping to launch the firm's 1st Bio Fund. Before becoming an investor, Zal spent 10 years as a PM at Microsoft, Google, Netflix, and LinkedIn. He worked on emerging markets for Windows, became one of the first monetization team members at YouTube, and then co-founded a consumer mobile startup. Later, he became the 1st Head of Mobile at Netflix and helped start the Sales Solutions business at LinkedIn. Zal also volunteered as a Kiva Fellow. He has a BS in Economics from Penn's Wharton School.

Advisors

Jeffrey Klausner

Professor at UCLA

Jeffrey Klausner

Dr. Jeffrey Klausner is Professor of Medicine in the Division of Infectious Diseases and the Program in Global Health at UCLA. He has also been a Deputy Health Officer, Director of STD Prevention and Control Services at the San Francisco Department of Public Health, member of the UCSF School of Medicine faculty in the Divisions of AIDS and Infectious Diseases, and Attending Physician at San Francisco General. He was previously Branch Chief for HIV and TB at the CDCl in Pretoria, South Africa. Dr. Klausner’s research interests are in applied epidemiology and the prevention and control of infectious diseases of public health importance like HIV, TB and Cryptococcus. He is a frequent advisor to the CDC, NIH and WHO, as well as a popular public speaker.

George Church

Professor at Harvard

George Church

George Church is Professor of Genetics at Harvard Medical School and Director of PersonalGenomes.org. His 1984 Harvard PhD included the first methods for direct genome sequencing and molecular multiplexing & barcoding, which led to the first genome sequence. His innovations have contributed to nearly all "next generation" DNA sequencing methods and companies. Dr. Church is director of an IARPA BRAIN Project and NIH Center for Excellence in Genomic Science. His honors include election to NAS and NAE, and the Franklin Bower Laureate for Achievement in Science. He has co-authored over 500 papers and one book.

Marc Unger

CEO of Hyalos Therapeutics

Marc Unger

Dr. Marc Unger received his PhD in Physical Chemistry at Caltech. During a postdoc in Applied Physics in Professor Steve Quake’s lab, he invented Multilayer Soft Lithography, the foundational technology of Fluidigm Corporation. The first paper describing the technology was published in Science and has now been cited more than 3000 times. He joined Fluidigm and drove the development of the core technology, manufacturing, and product lines; he also restructured and rebuilt the Marketing organization. During his tenure the company went public and achieved product revenues greater than $100M per year. He co-founded Hyalos Therapeutics in early 2017.

Investors

Backed by the best